Screener
ANI Pharmaceuticals ANIP Finance Lease Liabilities (Total)
Finance Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.
The source filing: ANI Pharmaceuticals’s 10-K, filed February 27, 2026.
- Filed
- Feb 27, 2026, 6:59 AM EST
- Fiscal year
- FY2025
- Accession
- 0001023024-26-000014
| (in thousands) | ||
|---|---|---|
| 2026 | $ | $150 |
| 2027 | 8 | |
| Total minimum lease payments | $ | $158 |
| Less: effects of discounting | (6) | |
| Present value of future minimum lease payments | 152 | |
| Less: current lease liability, included in accrued expenses and other | (104) | |
| Non-current lease liability, included in other non-current liabilities | $ | $48 |
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is ANI Pharmaceuticals's finance lease liabilities (total)?
- ANI Pharmaceuticals (ANIP) reported finance lease liabilities (total) of $152K in Q4 2025.
- What does finance lease liabilities (total) mean?
- Finance lease liabilities (total) represent the aggregate present value of all future lease payments for assets where the company assumes substantially all risks and rewards of ownership. This metric reflects the long-term debt-like burden associated with financing infrastructure or equipment through leases. It is a key component of the company's total leverage profile.
Ask your AI about ANI Pharmaceuticals's finance lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude